The article in Fierce Pharma today sums up why Vyvanse has experienced growth. "Gal had predicted that Concerta, which usually gains share during August--the month where kids who stopped taking "sit-quietly-in-class" drugs start them up again for the new school year--would cede share to Vyvanse, given the "mess" with Concerta generics. Back in November, the FDA gave Mallinckrodt ($MNK) and UCB 6 months to prove that their knockoffs were substitutable for the brand--or pull the copycats, which wear off more quickly than Concerta, from the market" however much our incompetent leadership tries to take credit for the year over year growth- which KK gloats about in her weekly pictorial- the fact is that Vyvanse has grown DESPITE their feeble and juvenile attempts to direct a sales force. luck is luck. Shire has gotten lucky with the fall of generic Concerta. Now maybe Shire can lucky again-if this pathetic leadership would move on to another company.
